

**Remarks/Arguments**

Applicants have amended the specification to provide the priority claim. Claims 14-15 have been canceled. Claims 16-19 have been amended. Claims 23-27 have been added. Claims 1-13 and 16-27 are pending after entry of this amendment. The claims have been amended to remove multiple dependencies and to otherwise place the claims in an appropriate U.S. format. No new matter has been added by these amendments.

A speedy Office Action on merit is respectfully requested.

The Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 26-0166, referencing Docket No. 101194-1P US.

Respectfully submitted,



Name: Jianzhong Shen  
Dated: March 22, 2006  
Reg. No. 48,076  
Phone No. 302-886-8854  
Global Intellectual Property, Patents,  
AstraZeneca,  
1800 Concord Pike,  
Wilmington,  
DE-19850-5437